The US Food and Drug Administration (FDA) has cleared Boehringer Ingelheim's tyrosine kinase inhibitor Gilotrif (afatinib) as a new medication for patients with late stage (metastatic) non-small cell lung cancer (NSCLC). The approval also ...
Tags: FDA, Lung Cancer Therapy, Medicine
Roche Group member Genentech and Astellas Pharma US announced that the US Food and Drug Administration (FDA) has cleared Tarceva (erlotinib). The tablets are used for the initial treatment of people with metastatic non-small cell lung ...
Tags: FDA, Tarceva Tablets, Astellas Pharma
The USFDA has accepted for filing Astellas Pharma's supplemental new drug application (sNDA) for Tarceva (erlotinib) tablets for a genetically distinct form of advanced lung cancer. Astellas is seeking approval to use Tarceva as the ...
Astellas Pharma US is seeking FDA approval for Tarceva tablets to treat non-small cell lung cancer patients (NSCLC) with tumors containing epidermal growth factor receptor (EGFR) that triggers mutations. The company submitted a ...
The Canadian Intellectual Property Office has issued a patent for Lorus Therapeutics' cancer immunotherapy agent, IL-17E. The patent protects the use of IL-17E to treat cancer, including solid tumors such as colon, breast, ovarian, ...
Tags: patent, IL-17E, treatment of cancer
Astellas Pharma has announced favorable US court ruling in patent infringement case for OSI Pharmaceuticals, Genentech, a member of the Roche Group, and Pfizer. The US District Court for the District of Delaware has found both the patents ...
Tags: Astellas Pharma, Mylan, lawsuit